首页> 外文期刊>European journal of pharmaceutical sciences >Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations
【24h】

Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations

机译:药用辅料-质量,法规和生物制药方面的考虑

获取原文
获取原文并翻译 | 示例
           

摘要

Practically all medications contain excipients, which are added for the purpose of production enhancement, patient acceptability, improving stability, controlling release etc. Typically excipients are the major components of a drug product, with the active molecule only present in relatively small amounts. Historically, excipients were termed inactive components. However, as highlighted in the present paper; excipients can have an impact on the absorption, distribution, metabolism and elimination (ADME) processes of the co-administered drug, which is important information when selecting excipients for any new formulation. Further, this review also provides a description of the regulatory processes to get new excipients approved in different regions and a discussion of the recent regulatory initiatives, e.g. excipients for paediatric formulations, thereby providing points to consider for the pharmaceutical scientist when selecting excipients for a new drug formulation. (C) 2015 Published by Elsevier B.V.
机译:实际上,所有药物都包含赋形剂,添加这些赋形剂是为了提高生产,患者可接受性,改善稳定性,控制释放等。赋形剂通常是药物产品的主要成分,活性分子仅以相对少量存在。历史上,赋形剂被称为非活性成分。但是,正如本文件所强调的那样;赋形剂可能会对共同给药药物的吸收,分布,代谢和消除(ADME)过程产生影响,这在为任何新制剂选择赋形剂时都是重要的信息。此外,本综述还描述了用于在不同地区获得批准的新赋形剂的监管程序,并讨论了最近的监管举措,例如:儿科制剂的赋形剂,从而为选择新药制剂的赋形剂提供了可供药学科学家考虑的要点。 (C)2015由Elsevier B.V.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号